You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: June 19, 2024

CLINICAL TRIALS PROFILE FOR RASBURICASE


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for rasburicase

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00057811 ↗ Rituximab, Rasburicase, and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Advanced B-Cell Leukemia or Lymphoma Completed National Cancer Institute (NCI) Phase 2 2004-06-01 Phase II trial to study the effectiveness of combining rituximab and rasburicase with combination chemotherapy in treating young patients who have newly diagnosed advanced B-cell leukemia or lymphoma. Monoclonal antibodies such as rituximab can locate cancer cells and either kill them or deliver cancer-killing substances to them without harming normal cells. Drugs used in chemotherapy work in different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug with rituximab may kill more cancer cells. Chemoprotective drugs such as rasburicase may protect kidney cells from the side effects of chemotherapy.
NCT00057811 ↗ Rituximab, Rasburicase, and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Advanced B-Cell Leukemia or Lymphoma Completed Children's Oncology Group Phase 2 2004-06-01 Phase II trial to study the effectiveness of combining rituximab and rasburicase with combination chemotherapy in treating young patients who have newly diagnosed advanced B-cell leukemia or lymphoma. Monoclonal antibodies such as rituximab can locate cancer cells and either kill them or deliver cancer-killing substances to them without harming normal cells. Drugs used in chemotherapy work in different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug with rituximab may kill more cancer cells. Chemoprotective drugs such as rasburicase may protect kidney cells from the side effects of chemotherapy.
NCT00186940 ↗ Rasburicase Treatment for Chemotherapy or Malignancy-Induced Hyperuricemia in Asthma/Allergy Patients Completed Sanofi 2005-03-01 This is a multi-center trial for rasburicase in children at high risk of tumor lysis syndrome who have a history of asthma/atopy. The main purpose of this study is to establish the safety of this drug in patients with a history of asthma or severe allergies.
NCT00186940 ↗ Rasburicase Treatment for Chemotherapy or Malignancy-Induced Hyperuricemia in Asthma/Allergy Patients Completed St. Jude Children's Research Hospital 2005-03-01 This is a multi-center trial for rasburicase in children at high risk of tumor lysis syndrome who have a history of asthma/atopy. The main purpose of this study is to establish the safety of this drug in patients with a history of asthma or severe allergies.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for rasburicase

Condition Name

Condition Name for rasburicase
Intervention Trials
Hyperuricemia 11
Tumor Lysis Syndrome 7
Lymphoma 6
Leukemia 5
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for rasburicase
Intervention Trials
Hyperuricemia 14
Tumor Lysis Syndrome 10
Lymphoma 10
Syndrome 8
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for rasburicase

Trials by Country

Trials by Country for rasburicase
Location Trials
United States 50
China 3
Italy 2
Germany 2
Belgium 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for rasburicase
Location Trials
Texas 6
California 5
New York 4
Pennsylvania 3
Florida 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for rasburicase

Clinical Trial Phase

Clinical Trial Phase for rasburicase
Clinical Trial Phase Trials
Phase 4 7
Phase 3 4
Phase 2 10
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for rasburicase
Clinical Trial Phase Trials
Completed 20
Terminated 4
Not yet recruiting 2
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for rasburicase

Sponsor Name

Sponsor Name for rasburicase
Sponsor Trials
Sanofi 14
M.D. Anderson Cancer Center 4
National Cancer Institute (NCI) 2
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for rasburicase
Sponsor Trials
Industry 18
Other 17
NIH 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.